Since Tuesday, October 8, French pharmacies can deliver the anti-obesity drug Wegovy to patients with a prescription. This treatment against obesity from the Novo Nordisk laboratory has been authorized in the European Union since January 2022 but in France its access was until then restricted: only eight thousand patients suffering from severe obesity were able to benefit from it.
Preventing diversions of anti-obesity aGLP-1 (GLP-1 analogues)
Wegovy is indicated in the treatment of severe obesity : it causes an average weight loss of around 15% of body weight after 68 weeks, according to the European Medicines Agency (source 1). This treatment is based on semaglutidelike Ozempic, indicated in France against diabetes and unfortunately misused by certain people to lose weight for purely aesthetic purposes.
Wegovy belongs to the aGLP-1 family (GLP-1 analogues). It is to prevent certain abuses that the National Medicines Agency, ANSM, has just published new measures to restrict the conditions of prescription and delivery of all aGLP-1 indicated in the treatment of obesity , namely the Wegs and the medicine Saxenda (liraglutide) (source 2).
Only certain medical specialists can prescribe Wegovy
aGLP-1s have in fact been diverted from their primary indication and…
Read more
Related News :